Sugi Predict

Sugi Predict / Compounds / SCHEMBL9900414

SCHEMBL9900414

SCHEMBL9900414

Cc1ccc(Oc2ncc([N+](=O)[O-])cn2)c2c1OCC2(C)C

nearest known ligand 0.35

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 5/20 0.35
▸ KMT2A Q03164 5/20 0.35
▸ RAB9A P51151 4/20 0.34
▸ MAPT P10636 6/20 0.33
▸ PKM P14618 1/20 0.33
▸ NPC1 O15118 3/20 0.32
▸ HSPB1 P04792 1/20 0.32
▸ MAPK1 P28482 2/20 0.31
▸ LMNA P02545 1/20 0.31
▸ PABPC1 P11940 1/20 0.31
▸ HTT P42858 2/20 0.31
▸ KDM4E B2RXH2 1/20 0.31
▸ ALDH1A1 P00352 3/20 0.31
▸ GAA P10253 1/20 0.31
▸ L3MBTL1 Q9Y468 1/20 0.31
▸ TSHR P16473 1/20 0.31
▸ TDP1 Q9NUW8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9904958 0.89 MEN1 (0.34) MEN1KMT2ARAB9AMAPTPKM
SCHEMBL9900628 0.86 HSPB1 (0.47) MEN1KMT2ARAB9AMAPTPKM
SCHEMBL15011541 0.83 KEAP1 (0.32) L3MBTL1
SCHEMBL9901409 0.81 MAPT (0.39) MEN1KMT2ARAB9AMAPTPKM
SCHEMBL9904832 0.76 HSPB1 (0.46) MEN1KMT2ARAB9AMAPTPKM
SCHEMBL17280423 0.73 — —
SCHEMBL30939643 0.73 — —
SCHEMBL19670207 0.72 — —
SCHEMBL25025637 0.72 — —
SCHEMBL9905733 0.71 KEAP1 (0.50) MEN1KMT2ARAB9AKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11583527-B2 Hydantoin derivatives useful as Kv3 inhibitors AUTIFONY THERAPEUTICS LIMITED (GB) 2023-02-21 — — US disclosed
US-11541052-B2 Compounds AUTIFONY THERAPEUTICS LIMITED (GB) 2023-01-03 — — US disclosed
US-20220054490-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2022-02-24 — — US disclosed
US-11197859-B2 Hydantoin derivatives useful as Kv3 inhibitors AUTIFONY THERAPEUTICS LIMITED (GB) 2021-12-14 — — US disclosed
US-20210023084-A1 NOVEL COMPOUNDS AUTIFONY SRL (IT) 2021-01-28 — — US disclosed
US-20200360379-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS GLAXOSMITHKLINE S.P.A. (IT) 2020-11-19 — — US disclosed
US-10835534-B2 Compounds AUTIFONY THERAPEUTICS LIMITED (GB) 2020-11-17 — — US disclosed
US-20200179385-A1 NOVEL COMPOUNDS AUTIFONY SRL (IT) 2020-06-11 — — US disclosed
US-10555945-B2 Compounds AUTIFONY THERAPEUTICS LIMITED (GB) 2020-02-11 — — US disclosed
US-20190192516-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS GLAXOSMITHKLINE S.P.A. (IT) 2019-06-27 — — US disclosed
US-20150336936-A1 NOVEL COMPOUNDS AUTIFONY SRL (IT) 2015-11-26 — — US disclosed
EP-2649066-B1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LTD (GB) 2015-10-21 — — EP disclosed
US-9133175-B2 Compounds AUTIFONY THERAPEUTICS LIMITED (GB) 2015-09-15 — — US disclosed
US-9133175-B2 Compounds AUTIFONY THERAPEUTICS LIMITED (GB) 2015-09-15 — — US disclosed
US-20140323508-A1 NOVEL COMPOUNDS AUTIFONY SRL (IT) 2014-10-30 — — US disclosed
US-20140323508-A1 NOVEL COMPOUNDS AUTIFONY SRL (IT) 2014-10-30 — — US disclosed
EP-2649066-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS Autifony Therapeutics Limited (GB) 2013-10-16 — — EP disclosed
US-20130267510-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2013-10-10 — — US disclosed
US-20130267510-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2013-10-10 — — US disclosed
WO-2012076877-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2012-06-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150336936-A1 NOVEL COMPOUNDS KCNN3, KCNN2, KCNN1 MEN1 1892/4885KMT2A 2759/4885RAB9A 1019/4885
US-20190192516-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS KCNN3, KCND3, KCNA3 MEN1 1596/4885KMT2A 635/4885RAB9A 1403/4885
US-11583527-B2 Hydantoin derivatives useful as Kv3 inhibitors KCNN3, KCND3, KCNA3 MEN1 1596/4885KMT2A 635/4885RAB9A 1403/4885
US-20220054490-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS KCNN3, KCND3, KCNA3 MEN1 1596/4885KMT2A 635/4885RAB9A 1403/4885
US-10835534-B2 Compounds KCNN3, KCNA3, KCNQ3 MEN1 724/4885KMT2A 1396/4885RAB9A 1460/4885
US-20200360379-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS KCNN3, KCND3, KCNA3 MEN1 1596/4885KMT2A 635/4885RAB9A 1403/4885
US-10555945-B2 Compounds KCNN3, KCNA3, KCNQ3 MEN1 724/4885KMT2A 1396/4885RAB9A 1460/4885
US-20200179385-A1 NOVEL COMPOUNDS KCNN3, KCND3, KCNA3 MEN1 1640/4885KMT2A 1821/4885RAB9A 1128/4885
US-20130267510-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS KCNA3, KCND3, KCNN3 MEN1 1367/4885KMT2A 450/4885RAB9A 1463/4885
US-11197859-B2 Hydantoin derivatives useful as Kv3 inhibitors KCNN3, KCND3, KCNA3 MEN1 1596/4885KMT2A 635/4885RAB9A 1403/4885
US-20210023084-A1 NOVEL COMPOUNDS KCNN3, KCND3, KCNA3 MEN1 1640/4885KMT2A 1821/4885RAB9A 1128/4885
US-20140323508-A1 NOVEL COMPOUNDS KCNN3, KCND3, KCNA3 MEN1 1640/4885KMT2A 1821/4885RAB9A 1128/4885
US-11541052-B2 Compounds KCNN3, KCNA3, KCNQ3 MEN1 724/4885KMT2A 1396/4885RAB9A 1460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.